An evidence-based update to the 2004 guidelines for the treatment of infantile spasms has recently been published. Important new recommendations include use of low-dose adrenocorticotropic hormone (ACTH) over high-dose ACTH or vigabatrin. A paucity of data, however, leaves several key questions unanswered.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Riikonen, R. in Long-term Evolution of Epileptic Encephalopathies (eds Nikanorova, M. et al.) 13–28 (John Libbey Eurotext, Esher, 2009).
Go, C. et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 78, 1974–1980 (2012).
Mackay, M. T. et al. Practice parameter: medical treatment of infantile spasms: report of American Academy of Neurology and Child Neurology Society. Neurology 62, 1668–1681 (2004).
Lux, A. L. et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomized controlled trial. Lancet 364, 1773–1778 (2004).
Riikonen, R. Long-term outcome of patients with West syndrome. Brain Dev. 23, 683–687 (2001).
Darke, K. et al. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multicentre randomized trial. Arch. Dis. Child. 95, 382–386 (2010).
Riikonen, R., Jääskeläinen, J. & Turpeinen, U. Insulin-like growth factor-1 is associated with cognitive outcome in infantile spasms. Epilepsia 51, 1283–1289 (2010).
Bittigau, P. Sifringer, M. & Ikonomidou, C. Antiepileptic drugs and apoptosis in the developing brain. Ann. NY Acad. Sci. 993, 103–114 (2003).
Moskowitz, A., Hansen, R. M., Eklund, S. E. & Fulton, A. B. Electroretinographic (ERG) responses in pediatric patients using vigabatrin. Doc. Ophthalmol. 124, 197–209 (2012).
Riikonen, R. Does vigabatrin treatment for infantile spasms bring visual field defects? Presented at the Joint 12th International Child Neurology Congress and 11th Asian and Oceanian Congress of Child Neurology, http://icnapedia.org/lectures/53-icnc2012/sig-meetings/2484-vigabatrin-visual-field-defects (2012).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Riikonen, R. Update to guidelines on treatment of infantile spasms. Nat Rev Neurol 8, 480–482 (2012). https://doi.org/10.1038/nrneurol.2012.157
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2012.157
This article is cited by
-
Stability and Pharmacological Effects of Gene-Recombinant Wild Type and Mutant Human Adrenocorticotropic Hormone
Pharmaceutical Research (2017)
-
Blitz-Nick-Salaam-Epilepsie
Monatsschrift Kinderheilkunde (2015)
-
Recent Advances in the Pharmacotherapy of Infantile Spasms
CNS Drugs (2014)